Weekly ICON Public Limited Company (NASDAQ:ICLR) Ratings as of May 16, 2018

May 16, 2018 - By Mary Markley

ICON Public Limited Company (NASDAQ:ICLR) Corporate Logo

ICON Public Limited Company (NASDAQ:ICLR) Ratings Coverage

In total 7 analysts cover Icon plc (NASDAQ:ICLR). “Buy” rating has 5, “Sell” are 0, while 2 are “Hold”. 71% are bullish. 10 are the (NASDAQ:ICLR)’s analyst reports since January 9, 2018 according to StockzIntelligence Inc. On Wednesday, January 24 the stock of ICON Public Limited Company (NASDAQ:ICLR) has “Hold” rating given by Mizuho. The company rating was downgraded by Evercore on Tuesday, April 3. On Thursday, February 15 the rating was maintained by Robert W. Baird with “Buy”. In Thursday, February 15 report Jefferies maintained the stock with “Buy” rating. On Tuesday, January 9 the stock of ICON Public Limited Company (NASDAQ:ICLR) earned “Buy” rating by Jefferies. The company rating was maintained by KeyBanc Capital Markets on Wednesday, January 10. On Monday, January 22 the rating was maintained by SunTrust with “Buy”. In Thursday, February 15 report Credit Suisse upgraded the stock to “Buy” rating. On Thursday, February 15 the rating was maintained by Mizuho with “Hold”. Listed here are ICON Public Limited Company (NASDAQ:ICLR) PTs and latest ratings.

03/04/2018 Broker: Evercore Old Rating: Outperform New Rating: In-Line Old Target: $126 Downgrade
15/02/2018 Broker: Robert W. Baird Rating: Buy New Target: $136.0 Maintain
15/02/2018 Broker: Jefferies Rating: Buy New Target: $141.0 Maintain
15/02/2018 Broker: Credit Suisse Rating: Buy New Target: $131.0 Upgrade
15/02/2018 Broker: Mizuho Rating: Hold New Target: $114.0 Maintain
24/01/2018 Broker: Mizuho Rating: Hold New Target: $109.0 Maintain
22/01/2018 Broker: SunTrust Rating: Buy New Target: $133.0 Maintain
19/01/2018 Broker: Evercore Rating: Outperform New Target: $126 Initiates Coverage On
10/01/2018 Broker: KeyBanc Capital Markets Rating: Buy New Target: $130.0 Maintain
09/01/2018 Broker: Jefferies Rating: Buy New Target: $145.0 Maintain

The stock decreased 0.64% or $0.79 during the last trading session, hitting $122.19.ICON Public Limited Company has volume of 239,918 shares. Since May 16, 2017 ICLR has risen 52.69% and is uptrending. ICLR outperformed the S&P500 by 41.14%.

ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally.The firm is valued at $6.61 billion. The firm specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.23.82 is the P/E ratio. The Company’s clinical development services comprise product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services.

For more ICON Public Limited Company (NASDAQ:ICLR) news brought out briefly go to: Businesswire.com, Seekingalpha.com, Seekingalpha.com, Businesswire.com or Streetinsider.com. The titles are as follows: “ICON Sponsors Industry-Wide Clinical Trials Survey to Support Transforming Trials Initiative” brought out on May 09, 2018, “ICON (ICLR) Q1 2018 Results – Earnings Call Transcript” on May 03, 2018, “Icon PLC Enjoying Wall Street Bonanza And FDA Tailwind” with a publish date: May 07, 2018, “Saama Technologies and ICON Commercialization and Outcomes Partner to Unlock the Value of Real World Evidence …” and the last “ICON plc (ICLR) Tops Q1 EPS by 2c, Updates Guidance” with publication date: May 03, 2018.

ICON Public Limited Company (NASDAQ:ICLR) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.